Cardiol Res

Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access

Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc

Journal website https://www.cardiologyres.org

Original Article

Volume 6, Number 1, February 2015, pages 209-215

The Effect of Intracoronary Stem Cell Injection on Markers of Leukocyte Activation in Acute Myocardial Infarction

Figure 2. Gene expression of PTX3 (panel a) and MPO (panel b) at follow-up relative to baseline in the randomly selected subset (n = 48) of the total population.

Figure 3. Correlation between plasma levels and gene expression levels of PTX3 in circulating leukocytes at baseline.

**Table 1.** Characteristics of the Study Population According to the Randomized Groups
	mBMC group (n = 50)	Control group (n = 50)
Values are given as mean (SD), proportions (n), medians (25, 75 percentiles) or percent (%). ACE-I: angiotensin-converting-enzyme inhibitor; ATII antagonist: antiotensin II antagonist; WBC: white blood cell.
Age	58.1 (8.5)	56.7 (9.6)
Sex (n of males)	42	42
Hypertension (n)	17	17
Diabetes (n)	5	4
Smokers (n)	20	40
BMI (kg/m²)	26.3 (3.9)	27.1 (3.5)
Total cholesterol (mmol/L)	4.4 (3.7 - 5.1)	4.5 (3.8 - 4.9)
LDL cholesterol (mmol/L)	2.9 (2.3 - 3.5)	2.9 (2.4 - 3.3)
HDL cholesterol (mmol/L)	1.0 (0.8 - 1.2)	1.0 (0.9 - 1.3)
Triglycerides (mmol/L)	1.3 (1.0 - 1.7)	1.3 (1.1 - 1.5)
LVEF (%)	43 (35, 48)	44 (34 - 49)
Peak CKMB (ng/L)	400 (220.5 - 447.0)	357 (205.0 - 423.0)
Baseline WBC count (10⁹/L)	8.1 (6.8 - 9.6)	8.4 (7.1 - 8.9)
Baseline neutrophile count (10⁹/L)	4.6 (3.8 - 5.9)	4.8 (4.1 - 5.9)
Medication at discharge
Aspirin (%)	100	100
Clopidogrel (%)	100	100
ACE-I/ATII antagonist (%)	100	98
Beta blocker (%)	100	100
Statin (%)	100	100
Diuretics (%)	42	32

Table 1. Characteristics of the Study Population According to the Randomized Groups

mBMC group (n = 50)

Control group (n = 50)

Values are given as mean (SD), proportions (n), medians (25, 75 percentiles) or percent (%). ACE-I: angiotensin-converting-enzyme inhibitor; ATII antagonist: antiotensin II antagonist; WBC: white blood cell.

Age

58.1 (8.5)

56.7 (9.6)

Sex (n of males)

Hypertension (n)

Diabetes (n)

Smokers (n)

BMI (kg/m²)

26.3 (3.9)

27.1 (3.5)

Total cholesterol (mmol/L)

4.4 (3.7 - 5.1)

4.5 (3.8 - 4.9)

LDL cholesterol (mmol/L)

2.9 (2.3 - 3.5)

2.9 (2.4 - 3.3)

HDL cholesterol (mmol/L)

1.0 (0.8 - 1.2)

1.0 (0.9 - 1.3)

Triglycerides (mmol/L)

1.3 (1.0 - 1.7)

1.3 (1.1 - 1.5)

LVEF (%)

43 (35, 48)

44 (34 - 49)

Peak CKMB (ng/L)

400 (220.5 - 447.0)

357 (205.0 - 423.0)

Baseline WBC count (10⁹/L)

8.1 (6.8 - 9.6)

8.4 (7.1 - 8.9)

Baseline neutrophile count (10⁹/L)

4.6 (3.8 - 5.9)

4.8 (4.1 - 5.9)

Medication at discharge

Aspirin (%)

100

Clopidogrel (%)

100

ACE-I/ATII antagonist (%)

100

Beta blocker (%)

100

Statin (%)

100

Diuretics (%)

**Table 2.** Plasma Levels of PTX3 and MPO According to the Randomized Groups at Baseline and Follow-Up
	Baseline	Day 1	Day 3	2 - 3 weeks	3 months
Values are given as median (25, 75 pencentiles).^§Difference in relative change from baseline (P < 0.05) between the groups. *Change from baseline (P < 0.05) within the respective treatment groups.
PTX3 (ng/mL)
mBMC group	0.92 (0.67 - 1.38)	0.91^§ (0.68 - 1.41)	0.84* (0.50 - 1.28)	0.74* (0.45 - 1.31)	0.62* (0.46 - 1.19)
Control group	1.18 (0.71 - 1.33)	0.76* (0.49 - 1.17)	0.73* (0.47 - 1.06)	0.68* (0.42 - 1.10)	0.68* (0.35 - 1.06)
MPO (ng/mL)
mBMC group	80 (60 - 120)	82* (60 - 106)	79 (57 - 106)	71* (54 - 98)	69* (49 - 92)
Control group	79 (59 - 115)	76 (54 - 101)	75* (61 - 92)	73* (53 - 83)	64* (48 - 88)

Table 2. Plasma Levels of PTX3 and MPO According to the Randomized Groups at Baseline and Follow-Up

Baseline

Day 1

Day 3

2 - 3 weeks

3 months

Values are given as median (25, 75 pencentiles).^§Difference in relative change from baseline (P < 0.05) between the groups. *Change from baseline (P < 0.05) within the respective treatment groups.

PTX3 (ng/mL)

mBMC group

0.92 (0.67 - 1.38)

0.91^§ (0.68 - 1.41)

0.84* (0.50 - 1.28)

0.74* (0.45 - 1.31)

0.62* (0.46 - 1.19)

Control group

1.18 (0.71 - 1.33)

0.76* (0.49 - 1.17)

0.73* (0.47 - 1.06)

0.68* (0.42 - 1.10)

0.68* (0.35 - 1.06)

MPO (ng/mL)

mBMC group

80 (60 - 120)

82* (60 - 106)

79 (57 - 106)

71* (54 - 98)

69* (49 - 92)

Control group

79 (59 - 115)

76 (54 - 101)

75* (61 - 92)

73* (53 - 83)

64* (48 - 88)

**Table 3.** Correlations Between Biomarkers, LVEF and Myocardial Necrosis
	Baseline PTX3	Baseline MPO
^§SPECT. *Proportion of LAD perfusion area.
Baseline LVEF^§	-0.110	0.290	-0.229	0.025
Infarct size*	-0.014	0.892	0.101	0.323
Peak CKMB	0.037	0.720	0.200	0.05

Table 3. Correlations Between Biomarkers, LVEF and Myocardial Necrosis

Baseline PTX3

Baseline MPO

^§SPECT. *Proportion of LAD perfusion area.

Baseline LVEF^§

-0.110

0.290

-0.229

0.025

Infarct size*

-0.014

0.892

0.101

0.323

Peak CKMB

0.037

0.720

0.200

0.05